資源描述：
《煙酰胺治療維持性血液透析患者高磷血癥的療效觀察》由會(huì)員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在學(xué)術(shù)論文-天天文庫(kù)。
1、萬(wàn)方數(shù)據(jù)溫州醫(yī)科大學(xué)碩士學(xué)位論文mmoFL比(2．35+0．36)mmol／L]均無(wú)統(tǒng)計(jì)學(xué)差異。煙酰胺不良反應(yīng)為胃腸道反應(yīng)(惡心、腹瀉為主)、皮膚瘀斑、頭痛等。煙酰胺治療組血小板較基礎(chǔ)值下降>30％的患者較對(duì)照組增加，二者具有顯著性統(tǒng)計(jì)學(xué)差異(尸=0．000)。結(jié)論本研究表明在服用磷結(jié)合劑治療的基礎(chǔ)上加用煙酰胺可對(duì)維持性血液透析高磷血癥患者起到良好的降磷作用，并帶來(lái)升高高密度脂蛋白的益處。主要不良反應(yīng)為胃腸道反應(yīng)和血小板減少，在治療時(shí)需監(jiān)測(cè)患者血小板。關(guān)鍵詞：煙酰胺；高磷血癥：腎透析；甲狀旁腺素萬(wàn)方數(shù)據(jù)溫州醫(yī)
2、科大學(xué)碩士學(xué)位論文EffectivenessofNiacinamideUsedonHyperphosphatemiaPatientsUndergoingHemodialysisAbstractObjectiveTostudytheeffectivenessandsafetyofniacinamideintreatingmaintenancehemodialysispatientswithhyperphosphatemia．MethodsItwasaprospectiveandrandomizedcontrol
3、ledtrial．Patientswithhyperphosphatemia(scramphosphate>1．45mmol／L)wererecruitedfromthehemodialysiscenteroftheFirstAffiliatedHospitalOfWenzhouMedicalUniversityandrandomlyassignedintotwogroups，controlgroupandniacinamidetherapygroup．Bothgroupsmaintainedtheftori
4、ginaldietaryhabit，dialysisscheme(dialysismode，dialysismembranematerial，weeklydialysistime，calciumconcentrationindialysissolution)，phosphatebinderandRocaltroltreatment．Niacinamidetherapygroupadditionallyreceivedniacinamide．ThestartingdosageWaS600mgperday．The
5、maximumdosageWas1200mgperday．Basicalmedicinesuchasantihypertensivedrug，ferralia，erythropoietin，levocarnitinecouldbeadjustedaccordingtopatient’Scondition．However,medicinewhichcouldinfluencetheabsorptionofphosphateorcalciumWasforbiddentobechanged．Thetreatment
6、lastedfor8weeks．NormalizedproteincatabolicrateWasmonthlytestedtoevaluatedietaryintake．Serumphosphateandcalciumweretestedevery2weeks，iPTH，hemoglobin，bloodplatelet，albumin，alkalinephosphatase，totalcholesterol，highdensitylipoprotein，lowdenskylipoprotein，trigly
7、cerideandotherrelevantindexesweretestedmonthly．Results100patientswererecruitedand93ofthemcompletedthetrial，including44fromthetherapygroupand49fromthecontrolgroup．Thereisnosignificantdifferencebetweentwogroupsinage，dialysisage，gender'weight，prescriptionofpho
8、sphatebindersandRocaRroLintakeofmedicinalcalcium，ureaclearanceindex，normalizedproteincatabolicrate．Beforethisexperiment，serumphosphatelevelintherapygroupWas1．95mmol／L，whilecontrolgroupWas1．93mmol／L．Att
